Mouse IL-6 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.36 pg/ml (10 μl) |
| Standard Curve Range | 8.19~2000 pg/ml |
| Standard Curve Gradient | 7 Points |
| Number of Incubations | 2 |
| Detectable sample | Liquid phase sample of soluble substances. For example: serum, plasma, cell culture supernatant, tissue grinding liquid, etc. |
| Sample Volume | 10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0176 | 0.0182 | 0.0179 | |
| 8.19 | 0.0346 | 0.0364 | 0.0355 | 0.0176 |
| 20.48 | 0.0681 | 0.0668 | 0.0675 | 0.0496 |
| 51.20 | 0.1466 | 0.1447 | 0.1457 | 0.1278 |
| 128.00 | 0.3521 | 0.3347 | 0.3434 | 0.3255 |
| 320.00 | 0.8173 | 0.8337 | 0.8255 | 0.8076 |
| 800.00 | 1.7570 | 1.7990 | 1.7780 | 1.7601 |
| 2000.00 | 3.3660 | 3.4510 | 3.4085 | 3.3906 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 40.7 | 199.7 | 642.4 | 37.3 | 177.3 | 585.0 |
| Standard Deviation | 1.2 | 7.1 | 23.6 | 1.7 | 5.3 | 17.7 |
| Coefficient of Variation(%) | 3.0 | 3.6 | 3.7 | 4.5 | 3.0 | 3.0 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested Twenty-two times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of mouse IL-6 into health mouse serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 80% to 95% with an overall mean recovery of 85%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | n.d.-16.26 | 93.3 | 4.35 |
Serum/Plasma – Thirty samples from apparently healthy mice were evaluated for the presence of IL-6 in this assay. No medical histories were available for the donors.
n.d. = non-detectable. Samples measured below the sensitivity are considered to be non-detectable.
Product Data Sheet
Background: IL-6
Interleukin 6 (IL-6) is a pleiotropic, a-helical, 22-28 kDa phosphorylated and variably glycosylated cytokine that plays important roles in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression. Mature human IL-6 is 183 amino acids (aa) in length and shares 39% aa sequence identity with mouse and rat IL-6. Alternative splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties. Cells known to express IL-6 include CD8+ T cells, fibroblasts, synoviocytes, adipocytes, osteoblasts, megakaryocytes, endothelial cells (under the influence of endothelins), sympathetic neurons, cerebral cortex neurons, adrenal medulla chromaffin cells, retinal pigment cells, mast cells, keratinocytes, Langerhans cells, fetal and adult astrocytes, neutrophils, monocytes, eosinophils, colonic epithelial cells, B1 B cells and pancreatic islet beta cells. IL-6 production is generally correlated with cell activation and is normally kept in control by glucocorticoids, catecholamines, and secondary sex steroids. Normal human circulating IL-6 is in the 1 pg/mL range, with slight elevations during the menstrual cycle, modest elevations in certain cancers, and large elevations after surgery.
IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R alpha) and a signal transducing subunit (gp130). IL-6 binds to IL-6 Ra, triggering IL-6 Ra association with gp130 and gp130 dimerization. gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM. Soluble forms of IL-6 Ra are generated by both alternative splicing and proteolytic cleavage. In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 Ra elicit responses from gp130-expressing cells that lack cell surface IL-6 Ra. Trans-signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 Ra is predominantly restricted to hepatocytes, monocytes, and resting lymphocytes. Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 Ra but not from other cytokines that use gp130 as a co-receptor.
IL-6, along with TNF-a and IL-1, drives the acute inflammatory response. IL-6 is almost solely responsible for fever and the acute phase response in the liver, and it is important in the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. When dysregulated, it contributes to chronic inflammation in conditions such as obesity, insulin resistance, inflammatory bowel disease, arthritis, and sepsis. IL-6 modulates bone resorption and is a major effector of inflammatory joint destruction in rheumatoid arthritis through its promotion of Th17 cell development and activity. It contributes to atherosclerotic plaque development and destabilization as well as the development of inflammation-associated carcinogenesis.
Under construction!
Under construction!
Under construction!
Citations
-
Interleukin-17 alleviates erastin-induced alveolar bone loss by suppressing ferroptosis via interaction between NRF2 and p-STAT3
Applications: ELISA
Reactivity: Mouse
Publish Date: 2023 Nov
-
Luteolin attenuates RA-associated chronic pain by targeting the LDHA/H3K9la/NFATC2 axis to suppress Th17 cell differentiation and central infiltration
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Jun
-
Harmine derivative ZLWH-38 ameliorates the therapeutic efficacy of colistin against XDR-Ab pneumonia by suppressing inflammatory responses
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Sept
-
Lipocalin 2 deficiency attenuates NLRP3 inflammasome activation through glycolysis impairment and MGST1-mediated mitochondrial ROS reduction
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Nov
-
Deciphering the Role of N-Acetyltransferase 10 in Thalamic Hemorrhage Through Integrative Multi-Omics and Experimental Validation
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Nov
-
An antibacterial, antioxidant and hemostatic hydrogel accelerates infectious wound healing
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Jan
-
Recombinant human collagen XVII promotes skin repair and regeneration by upregulating Lgr6 signaling pathway
Applications: ELISA
Reactivity: Mouse
Publish Date: 2025 Dec
-
Gambogic acid suppresses pancreatic fibrosis via inhibiting YAP1-mediated activation of pancreatic stellate cells
Applications: ELISA
Reactivity: Rat
Publish Date: 2026 Jan
-
Engineered Sporopollenin Exine Capsules for Colon-Targeted Delivery and Antioxidant Therapy of Pogostemon Oil in Ulcerative Colitis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jan
-
Investigating the role of SMOX in rheumatoid arthritis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jan
-
Functional Restoration of Uterine Architecture and Fertility via a 3D-Printed Biomimetic Scaffold: The Role of Macrophage-Driven Immunomodulation
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Feb
-
A novel DYRK1A inhibitor alleviates lipopolysaccharide-induced acute lung injury via suppressing inflammatory pathway
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Feb
-
Colonic Engyodontium fungus triggers neutrophil antimicrobial activity to suppress Lactobacillus johnsonii-derived glutamic acid-maintained Tregs
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Mar
-
Engineered M2 macrophage-derived vesicles deliver DNase I for cfDNA clearance and multi-organ protection in sepsis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Mar
-
Neuromodulation and Copper Chelation Reverse Sleep Fragmentation–Aggravated Myocardial Ischemia-Reperfusion Injury by Targeting NETs-Induced Endothelial Cuproptosis
Applications: ELISA
Reactivity:
Publish Date: 2026 Apr
-
Hexokinase 3 promoted cytokine production of monocytes by targeting metabolic reprogramming and histone lactylation in sepsis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Apr
-
Erbin Confers Neuroprotection Against Cerebral Ischemia-Reperfusion Injury in Mice via MAPK Pathway Inhibition
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Apr
-
Signaling Pathway Involved in Macrophage Activation by Fructose-Enriched Polysaccharides From Baizhu Shaoyao Powder
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Apr
-
Sleep deprivation induces anxiety-like behaviors through IL-6 driven astrocyte-GABAergic neuron crosstalk in the PAG-ACC circuit
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 May
-
Fusobacterium nucleatum-derived succinic acid aggravates colitis by triggering macrophage pro-inflammatory phenotypic transformation via SUCNR1/NF-κB axis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jul
-
Targeted Delivery of Schisandrin A to Cardiac Endothelium Alleviates Myocardial Ischemia-Reperfusion Injury via Suppression of Ferroptosis
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Jul
-
Strontium-incorporated thermoresponsive hydrogel platform co-delivering graphene oxide-mannose nanocomplexes: An osteoimmunomodulatory strategy for periodontitis therapy
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Aug
-
IDO1 Inhibitor RY103 Prevents Sepsis-Associated Immunosuppression in Cecal Ligation and Puncture Mice
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Aug
-
MYC-Sensitized Cuproptosis Combined With PTT to Remodel the Immune Microenvironment of Prostate Cancer
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Brassica rapa L. (Turnip) Ethanol Extract Alleviates Hyperuricemia by Modulating Purine Metabolism Enzymes and Renal Urate Transporters
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Bifidobacterium longum Subspecies infantis M63 Enhances the Colitis-Alleviating Effect of 2′-Fucosyllactose by Restoring Intestinal Barrier Function and Microbial Metabolism
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Hemolytic mechanism and virulence of Antarctic psychrophilic Pseudomonas
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
-
Therapeutic Potential of Thiosemicarbazone Derivative in LPS‐Induced Mastitis: Dual Modulation of Inflammatory Response and Blood–Milk Barrier Integrity
Applications: ELISA
Reactivity: Mouse
Publish Date: 2026 Sept
